Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR-DIM in Stage II-III TNBC and AR+ Breast Cancer
NCT01612910Phase 2Withdrawn
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jun 2012
- Primary completion
- Feb 2014
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of 3,3'-diindolylmethane in breast cancer, sponsored by Barbara Ann Karmanos Cancer Institute. Planned start Jun 2012; status: withdrawn.
02
Drugs
3,3'-diindolylmethane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01612910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01612910.